Andre Rogatko, PhD
Director, Biostatistics and Bioinformatics, Samuel Oschin Comprehensive Cancer Institute
|Samuel Oschin Comprehensive Cancer Institute|
Statistical method to improve the design and analysis of clinical trials, genetic epidemiology and risk prediction.
Developed a new approach for dose escalation in cancer phase I clinical trials: EWOC (Escalation With Overdose Control), which selects doses of an agent while controlling the probability of exceeding the maximum tolerated dose. The extension of EWOC to covariate utilization made it the first method described to design cancer clinical trials that not only guides dose escalation, but also permits personalization of the dose level for each specific patient.
Proposed methods to construct meiotic gene maps while controlling the probability of a decision-error and to characterize diagnostic tests with multi-valued outcomes. Developed two diagnostics for the statistical assessment of the Hardy-Weinberg Equilibrium and the first Bayesian method for metanalysis of clinical trials.
Current investigations include:
Bayesian methods to personalize cancer treatment and improve the design of cancer trials.
- Rogatko A, Schoeneck D, Jonas W, Tighiouart M, Khuri FR, Porter A: Translation of innovative designs into phase I trials. J. Clin. Oncol., 25(31): 4982-6, 2007
- Babb J, Rogatko A, Zacks S: Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat Med, 17(10): 1103-20, 1998
- Rogatko A, Babb J, Jordan H, Zacks S: Constructing meiotic maps with known error probability. Genet. Epidemiol., 16(3): 274-89, 1999
- Rogatko A, Slifker MJ, Babb JS: Hardy-Weinberg equilibrium diagnostics. Theor Popul Biol, 62(3): 251-7, 2002
- Rogatko A, Babb JS, Tighiouart M, Khuri FR, Hudes G: New paradigm in dose-finding trials: patient-specific dosing and beyond phase I. Clin. Cancer Res., 11(15): 5342-6, 2005
- Rogatko A, Babb JS, Wang H, Slifker MJ, Hudes GR: Patient characteristics compete with dose as predictors of acute treatment toxicity in early phase clinical trials. Clin. Cancer Res., 10(14): 4645-51, 2004